Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biosimilar
Pharma
China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China's alternative trial pathway draws scrutiny. AZ and Daiichi Sankyo's phase 3 lung cancer win. Tanabe's licensing deal. And more.
Donavyn Coffey
Aug 21, 2026 9:00am
Fresenius Kabi launches US recall of Actemra biosimilar
Aug 12, 2026 9:13am
Amneal, BioCorRx accused of ‘false and misleading’ promotions
Apr 10, 2026 8:41am
New egg-based drugmaker Neion Bio strikes biosimilar collab
Mar 26, 2026 1:00pm
Inside the turning tides of the US biosimilar market
Jan 8, 2026 9:00am
Sandoz's biosimilar to Biogen's Tysabri hits the US after delay
Nov 17, 2025 11:12am
